FDA Approves Another SGLT2 Inhibitor for Treating CKD
(MedPage Today) -- The SGLT2 inhibitor empagliflozin (Jardiance) nabbed a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes status, Boehringer Ingelheim and Eli Lilly announced.
Data from the phase...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | SGLT2 Inhibitors | Urology & Nephrology